Search NLS News

The company carries out a directed share issue to a limited number of current shareholders in the company, such as Gerald Engström who, following the Share Issue, becomes the largest shareholder. In addition, Andra AP-Fonden, Humle Fonder, Cicero Fonder, as well as the member of the Board of Directors, and until now the largest shareholder, […]

With this acquisition Scantox has nearly 200 employees across four sites. “Scantox embarked on an ambitious growth journey when we acquired the first two international companies last year, and we are thrilled to now expand our Group further with the acquisition of Q&Q. We welcome a company known for their solid expertise within the field […]

The Novo Nordisk Foundation has committed up to DKK 950 million (EUR 127 million) to establish a world-class facility for the final development steps and upscaling of cell therapies for testing in humans. The Novo Nordisk Foundation Cellerator will fill a critical gap in the Danish cell therapy ecosystem, helping to translate breakthroughs in cell […]

The European Commission has granted conditional marketing authorization for TEPKINLY as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in […]

Novo Nordisk and Valo Health have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases based on Valo’s large human dataset and computation powered by artificial intelligence (AI). The collaboration will leverage the capabilities of Valo’s Opal Computational Platform including access to real-world patient data, AI-enabled small molecule discovery and Biowire […]

Cyto-Facto Inc. began manufacturing gene and cell preparations to meet a worldwide need for new treatments that leverage a patient’s immune system to fight disease. CF implemented the Vaisala viewLinc continuous monitoring system to ensure compliance with strict GCTP regulations. In April 2023, Cyto-Facto Inc. (CF), a spin-off of the Foundation for Biomedical Research and […]

BioArctic’s partner Eisai has announced that “LEQEMBI Intravenous Infusion” has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease. The regulatory approval in Japan entitles BioArctic to a milestone of EUR 17 million. “The approval of LEQEMBI in Japan is another important […]

It’s no secret that it’s been a challenging 12 months for the life sciences and healthcare sector. With generalist investors moving out of the public markets in 2022 after the boom of 2020 and 2021, and not yet returning in numbers, this slowdown has depressed the IPO market and fed through down to private investment, […]

The two collaborators aim to develop a prophylactic vaccine based on Evaxion’s EDEN-discovered gonorrhea targets. “We are thrilled about this partnership. It offers a unique opportunity to deliver our EDEN-identified antigens using mRNA and it accelerates clinical validation of the EDEN platform. This partnership has the potential to address a serious unmet global medical need […]

An international team of scientists led by the University of Helsinki performed comprehensive mapping of structural alterations in cellular proteins during the aging process. In the study published in Molecular Cell, the team mapped structural alterations in cellular proteins during the aging process and, in the process, identifying new ways aging impacts how cells hum […]